Edwards, Medtronic post low-risk TAVR data, allaying fears of market disruption

Edwards Lifesciences and Medtronic reported new data on their transcatheter aortic-valve replacement (TAVR) devices that show no significant difference between the procedure and open-heart surgery in low-risk patients. Analysts predicted the market will continue on the same trajectory after the results were shared at TCT 2023.